CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Other acquisition Director acquired 8,217 shares (other)
- 4 Other acquisition President and CEO acquired 18,793 shares (other)
- 4 Other disposition Chief Financial Officer disposed of 237,155 shares (other)
- 4 Gift Director gave 446,623 shares (gift)
- 4 Other acquisition President and CEO acquired 18,793 shares (other)
- 4 Other acquisition President and CEO acquired 18,793 shares (other)
- 4 Other acquisition Director acquired 8,217 shares (other)
- 4 Other acquisition President and CEO acquired 18,793 shares (other)
- 4 Other acquisition Director acquired 8,217 shares (other)
- 4 Open-market sale Chief Technical Officer sold 48,827 shares at an average $32.11 ($1,567,666)
- 4 Other acquisition President and CEO acquired 18,793 shares (other)
- 4 Other acquisition Director acquired 8,217 shares (other)
- 4 Grant or award EVP of R&D and CMO acquired 105,162 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Technical Officer sold 48,827 shares at an average $29.44 ($1,437,603)
- 4 Other acquisition Director acquired 8,217 shares (other)
- 4 Other acquisition President and CEO acquired 18,793 shares (other)
- 4 Other acquisition Director acquired 5,590 shares (other)
- 4 Other acquisition President and CEO acquired 16,542 shares (other)
- 4 Exercise or conversion Chief Technical Officer acquired 27,816 shares (option exercise)
Page 12 of 14 · 275 filings